{"Pembrolizumab": [0], "demonstrated": [1], "antitumor": [2], "activity": [3], "and": [4, 25, 81, 93, 118, 139, 219, 260, 277, 293], "safety": [5, 26], "in": [6, 12, 29, 43, 104, 257, 274, 318], "the": [7, 23, 205], "phase": [8, 34], "II": [9], "KEYNOTE-224": [10], "trial": [11], "previously": [13, 51], "treated": [14, 52], "patients": [15, 47, 106, 123, 262, 279], "with": [16, 48, 53, 307], "advanced": [17, 49], "hepatocellular": [18], "carcinoma": [19], "(HCC).": [20], "KEYNOTE-240": [21], "evaluated": [22], "efficacy": [24], "of": [27, 112, 128, 309], "pembrolizumab": [28, 64, 138, 156, 183, 265, 317], "this": [30, 290, 319], "population.This": [31], "randomized,": [32], "double-blind,": [33], "III": [35], "study": [36, 113], "was": [37, 102, 134, 146, 184], "conducted": [38], "at": [39, 58, 204, 237], "119": [40], "medical": [41], "centers": [42], "27": [44], "countries.": [45], "Eligible": [46], "HCC,": [50], "sorafenib,": [54], "were": [55, 77, 124, 270, 288], "randomly": [56, 125], "assigned": [57], "a": [59, 312], "two-to-one": [60], "ratio": [61, 169, 315], "to": [62, 152, 163, 175, 190, 199, 214, 225, 234, 245], "receive": [63], "plus": [65, 72], "best": [66], "supportive": [67], "care": [68], "(BSC)": [69], "or": [70, 252, 285], "placebo": [71, 167, 203], "BSC.": [73], "Primary": [74], "end": [75], "points": [76], "overall": [78], "survival": [79, 83], "(OS)": [80], "progression-free": [82], "(PFS;": [84], "one-sided": [85], "significance": [86, 299], "thresholds,": [87], "P": [88, 94, 177, 216, 247], "=": [89, 95, 178, 217, 248], ".0174": [90], "[final": [91], "analysis]": [92], ".002": [96], "[first": [97], "interim": [98, 207], "analysis],": [99], "respectively).": [100], "Safety": [101], "assessed": [103], "all": [105], "who": [107], "received": [108], "\u2265": [109], "1": [110], "dose": [111], "drug.Between": [114], "May": [115], "31,": [116], "2016,": [117], "November": [119], "23,": [120], "2017,": [121], "413": [122], "assigned.": [126], "As": [127], "January": [129], "2,": [130], "2019,": [131], "median": [132], "follow-up": [133], "13.8": [135], "months": [136, 141, 148, 159, 186, 195, 221, 230], "for": [137, 142, 155, 166, 182, 202, 264, 316], "10.6": [140, 158], "placebo.": [143], "Median": [144, 180], "OS": [145, 292], "13.9": [147], "(95%": [149, 160, 187, 196, 222, 231], "CI,": [150, 161, 173, 188, 197, 212, 223, 232, 243], "11.6": [151], "16.0": [153], "months)": [154, 165, 192, 201, 227, 236], "versus": [157, 193, 228, 266], "8.3": [162], "13.5": [164], "(hazard": [168], "[HR],": [170], "0.781;": [171], "95%": [172, 211, 242], "0.611": [174], "0.998;": [176], ".0238).": [179], "PFS": [181, 294], "3.0": [185, 220, 235], "2.8": [189, 194, 224, 229], "4.1": [191, 200, 226], "2.5": [198], "first": [206], "analysis": [208, 239], "(HR,": [209, 240], "0.775;": [210], "0.609": [213], "0.987;": [215], ".0186)": [218], "1.6": [233], "final": [238], "0.718;": [241], "0.570": [244], "0.904;": [246], ".0022).": [249], "Grade": [250], "3": [251], "higher": [253], "adverse": [254], "events": [255], "occurred": [256, 273], "147": [258], "(52.7%)": [259], "62": [261], "(46.3%)": [263], "placebo;": [267], "those": [268, 308], "that": [269], "treatment": [271], "related": [272], "52": [275], "(18.6%)": [276], "10": [278], "(7.5%),": [280], "respectively.": [281], "No": [282], "hepatitis": [283], "C": [284], "B": [286], "flares": [287], "identified.In": [289], "study,": [291], "did": [295], "not": [296], "reach": [297], "statistical": [298], "per": [300], "specified": [301], "criteria.": [302], "The": [303], "results": [304], "are": [305], "consistent": [306], "KEYNOTE-224,": [310], "supporting": [311], "favorable": [313], "risk-to-benefit": [314], "population.": [320]}